Table 6.
Predictors of i‐TTR (%) in Warfarin Patients by Multiple Linear Regression Modeling: Geographical Site of Recruitment Grouped as Countries
| Baseline Characteristic | Multivariable | |||
|---|---|---|---|---|
| Parameter Estimate | F | P Value | Partial R2 | |
| VKA experience | 74.94 | <0.0001 | 0.0217 | |
| Warfarin experienced | Ref | |||
| VKA experienced/warfarin naïve | −7.399 | |||
| VKA naïve | −2.153 | |||
| CHF | −2.373 | 20.19 | <0.0001 | 0.0029 |
| Country | 13.73 | <0.0001 | 0.0876 | |
| United States | Ref | |||
| Argentina | −1.486 | |||
| Australia | 7.531 | |||
| Austria | 5.945 | |||
| Belgium | −3.014 | |||
| Brazil | −7.721 | |||
| Bulgaria | −9.669 | |||
| Canada | 2.801 | |||
| Chile | −0.302 | |||
| China | −11.081 | |||
| Colombia | −8.315 | |||
| Czech Republic | −1.641 | |||
| Denmark | 1.548 | |||
| Finland | 4.294 | |||
| France | 1.180 | |||
| Germany | −1.600 | |||
| Greece | −7.210 | |||
| Hong Kong | 3.003 | |||
| Hungary | −3.170 | |||
| India | −21.495 | |||
| Israel | −4.492 | |||
| Italy | 3.818 | |||
| Korea | −14.885 | |||
| Lithuania | −10.173 | |||
| Malaysia | −4.867 | |||
| Mexico | −10.713 | |||
| Netherlands | −0.160 | |||
| New Zealand | 9.905 | |||
| Norway | 4.564 | |||
| Peru | −2.116 | |||
| Philippines | −3.744 | |||
| Poland | −1.884 | |||
| Romania | −10.103 | |||
| Russia | −10.903 | |||
| Singapore | 2.828 | |||
| South Africa | −7.806 | |||
| Spain | −2.821 | |||
| Sweden | 12.009 | |||
| Switzerland | −10.068 | |||
| Taiwan | −20.772 | |||
| Thailand | −3.865 | |||
| Turkey | −16.503 | |||
| Ukraine | −13.930 | |||
| United Kingdom | 6.014 | |||
| Venezuela | −20.635 | |||
| COPD | −2.669 | 11.91 | 0.0006 | 0.0017 |
| Female | −6.275 | 10.24 | 0.0014 | 0.0015 |
| Diabetes | −1.598 | 10.22 | 0.0014 | 0.0015 |
| BMI | 0.0022 | |||
| Linear | 0.744 | 9.14 | 0.0025 | |
| Quadratic | −0.010 | 6.58 | 0.010 | |
| Systolic BP | −0.037 | 6.28 | 0.012 | 0.0009 |
| Hemoglobin, 2 g/L | 0.0014 | |||
| Linear | −4.654 | 3.11 | 0.078 | |
| Quadratic | 0.109 | 0.78 | 0.38 | |
| eGFR, 10 mL/min per 1.73 m2 | 0.0013 | |||
| Linear | −3.478 | 3.26 | 0.071 | |
| Quadratic | 0.073 | 0.90 | 0.34 | |
| Alcohol consumption, 12 mo | 2.41 | 0.065 | 0.0010 | |
| Abstinent | Ref | |||
| Light | 0.838 | |||
| Moderate | 1.624 | |||
| Heavy | −5.340 | |||
| Medications at entry to the trial | ||||
| Amiodarone | −2.616 | 8.74 | 0.0031 | 0.0013 |
| Statin | 0.818 | 2.63 | 0.11 | 0.0004 |
| Aspirin | −0.619 | 1.25 | 0.26 | 0.0002 |
i‐TTR indicates individual patient‐level time in therapeutic range; VKA, vitamin K antagonist; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; BMI, body mass index; BP, blood pressure; eGFR, estimated glomerular filtration rate.